Abstract
Get full access to this article
View all access options for this article.
References
1.Regeneron Pharmaceuticals . Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S . 2026 . Available from: https://investor.regeneron.com/news-releases/news-release-details/otarmenitm-lunsotogene-parvec-cwha-approved-fda-first-and-only [Last accessed May 1 , 2026
2.Intellia Therapeutics . Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing . 2026 . Available from: https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-positive-phase-3-results [Last accessed: May 1 , 2026
3.Genetic Engineering & Biotechnology News . Genomics Pioneer and Life Sciences Entrepreneur J. Craig Venter Dies at 79 . 2026 . Available from: https://www.genengnews.com/topics/omics/genomics-pioneer-and-life-sciences-entrepreneur-j-craig-venter-dies-at-79/ [Last accessed: May 1 , 2026
4.J. Craig Venter Institute . J. Craig Venter, genomics pioneer and founder of JCVI and Diploid Genomics, Inc., dies at 79 . 2026 . Available from: https://www.jcvi.org/media-center/j-craig-venter-genomics-pioneer-and-founder-jcvi-and-diploid-genomics-inc-dies-79 [Last accessed: May 1 , 2026
5.Rocket Pharmaceuticals . Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher . 2026 . Available from: https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-announces-180-million-sale-priority/ [Last accessed: May 3 , 2026
6.Passage Bio . Form 8-K, filed . 2026 . Available from: https://d18rn0p25nwr6d.cloudfront.net/CIK-0001787297/eb92a761-f51e-4ff7-8efc-755a63bcee48.pdf [Last accessed: May 5 , 2026
7.LEO Pharma . LEO Pharma bolsters rare skin disease focus through acquisition of Replay gene therapy platform . 2026 . Available from: https://www.leo-pharma.com/media-center/news/2026-leo-pharma-acquires-replay [Last accessed: May 3 , 2026
8.MeiraGTx Holdings . MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) . 2026 . Available from: https://investors.meiragtx.com/news-releases/news-release-details/meiragtx-announces-acquisition-botaretigene-sparoparvovec-bota [Last accessed: May 3 , 2026